Acorda Signs Settlement With Mylan on Generic Ampyra

   By Michael Dabaie 
 

Biotechnology company Acorda Therapeutics Inc. (ACOR) on Friday said it signed a conditioned settlement agreement with Mylan N.V. (MYL) and affiliates over Acorda's multiple-sclerosis drug Ampyra.

Under the settlement agreement, Mylan will be permitted to market its generic version of Ampyra in the U.S. sometime in 2025 or earlier under certain circumstances, Acorda said in a filing with the Securities and Exchange Commission.

Acorda also said it signed interim agreements with Teva Pharmaceutical Industries Ltd. (TEVA) and Hikma Pharmaceuticals PLC (HKMPY) concerning their patent litigation relating to Ampyra.

Acorda is awaiting a decision of the U.S. Court of Appeals for the Federal Circuit in its appeal of a 2017 U.S. district court decision that invalidated four of its Ampyra patents set to expire between 2025 and 2027.

Acorda earlier this week reiterated it sees Ampyra 2018 net revenue of $330 million to $350 million.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

August 03, 2018 09:24 ET (13:24 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.